Repligen Company Leadership
| RGEN Stock | USD 141.76 2.86 2.06% |
About 88 percent of Repligen's insiders are activelly selling. The analysis of insiders' sentiment of trading Repligen stock suggests that quite a large number of insiders are panicking at this time. Repligen employs about 1.8 K people. The company is managed by 19 executives with a total tenure of roughly 27 years, averaging almost 1.0 years of service per executive, having 93.84 employees per reported executive.
| Anthony Hunt CEO President CEO, Director |
| Ralf Kuriyel President Senior Vice President - Research & Development |
Repligen's Insider Buying Vs Selling
12
Selling | Buying |
Latest Trades
| 2024-09-10 | Anthony Hunt | Disposed 22191 @ 145.37 | View | ||
| 2024-08-01 | Ralf Kuriyel | Disposed 4465 @ 165.67 | View | ||
| 2024-06-14 | Martin D Madaus | Acquired 1615 @ 124.94 | View | ||
| 2024-05-21 | Anthony Hunt | Disposed 20072 @ 168.26 | View | ||
| 2024-03-11 | Ralf Kuriyel | Disposed 3517 @ 193.73 | View | ||
| 2024-03-08 | Anthony Hunt | Disposed 16707 @ 197.44 | View | ||
| 2024-02-27 | Karen A Dawes | Disposed 1000 @ 193.35 | View | ||
| 2024-02-23 | James Bylund | Disposed 4373 @ 198.08 | View |
Monitoring Repligen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Repligen |
Repligen's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Repligen's future performance. Based on our forecasts, it is anticipated that Repligen will maintain a workforce of about 1780 employees by December 2024.Repligen Management Team Effectiveness
As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.02. At this time, Repligen's Intangible Assets are very stable compared to the past year. As of the 22nd of November 2024, Net Tangible Assets is likely to grow to about 847.1 M, while Deferred Long Term Asset Charges is likely to drop about 2.2 M. Repligen's management efficiency ratios could be used to measure how well Repligen manages its routine affairs as well as how well it operates its assets and liabilities.As of the 22nd of November 2024, Net Income Applicable To Common Shares is likely to grow to about 224.5 M, while Common Stock Shares Outstanding is likely to drop about 29.9 M.
Repligen Workforce Comparison
Repligen is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 183,704. Repligen maintains roughly 1,783 in number of employees contributing less than 1% to equities under Health Care industry.
Repligen Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repligen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repligen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Repligen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 1.0 | 1 | 1 | 19,000 | 19,000 |
| 2024-09-01 | 0.8889 | 8 | 9 | 64,259 | 60,007 |
| 2024-06-01 | 2.4444 | 22 | 9 | 27,639 | 21,384 |
| 2024-03-01 | 0.963 | 26 | 27 | 94,399 | 46,816 |
| 2023-12-01 | 1.0 | 2 | 2 | 37,142 | 4,788 |
| 2023-09-01 | 4.0 | 4 | 1 | 30,811 | 850.00 |
| 2023-06-01 | 4.25 | 17 | 4 | 17,066 | 2,088 |
| 2023-03-01 | 1.1176 | 19 | 17 | 114,598 | 35,994 |
| 2022-12-01 | 4.0 | 4 | 1 | 50,932 | 25,000 |
| 2022-09-01 | 1.2727 | 14 | 11 | 33,358 | 53,098 |
| 2022-06-01 | 1.7778 | 16 | 9 | 25,152 | 16,809 |
| 2022-03-01 | 1.087 | 25 | 23 | 118,226 | 39,063 |
| 2021-12-01 | 0.2333 | 7 | 30 | 21,208 | 42,411 |
| 2021-09-01 | 0.2368 | 9 | 38 | 66,735 | 66,371 |
| 2021-06-01 | 0.8824 | 15 | 17 | 28,768 | 49,941 |
| 2021-03-01 | 0.2 | 11 | 55 | 33,478 | 97,842 |
| 2020-12-01 | 0.3846 | 5 | 13 | 26,847 | 52,567 |
| 2020-09-01 | 0.4444 | 4 | 9 | 54,569 | 103,797 |
| 2020-06-01 | 0.4912 | 28 | 57 | 132,763 | 240,186 |
| 2020-03-01 | 0.3864 | 17 | 44 | 97,551 | 177,901 |
| 2019-12-01 | 0.6667 | 2 | 3 | 3,957 | 4,252 |
| 2019-09-01 | 0.0833 | 1 | 12 | 20,000 | 35,989 |
| 2019-06-01 | 1.7778 | 16 | 9 | 79,405 | 60,295 |
| 2019-03-01 | 1.0909 | 12 | 11 | 109,142 | 48,437 |
| 2018-12-01 | 0.5714 | 4 | 7 | 31,753 | 65,580 |
| 2018-09-01 | 0.3333 | 5 | 15 | 16,301 | 237,568 |
| 2018-06-01 | 0.75 | 15 | 20 | 78,022 | 518,257 |
| 2018-03-01 | 1.2 | 12 | 10 | 620,835 | 49,657 |
| 2017-12-01 | 0.6 | 3 | 5 | 12,729 | 925,458 |
| 2017-06-01 | 12.0 | 12 | 1 | 23,373 | 2,275 |
| 2017-03-01 | 1.0667 | 16 | 15 | 303,765 | 74,292 |
| 2016-09-01 | 0.5 | 1 | 2 | 20,000 | 3,024 |
| 2016-06-01 | 2.125 | 17 | 8 | 68,062 | 51,493 |
| 2016-03-01 | 2.0 | 10 | 5 | 178,940 | 6,484 |
| 2015-12-01 | 3.0 | 3 | 1 | 7,000 | 5,000 |
| 2015-09-01 | 1.0 | 1 | 1 | 24,000 | 325.00 |
| 2015-06-01 | 1.4 | 14 | 10 | 26,388 | 232,625 |
| 2015-03-01 | 1.25 | 10 | 8 | 119,519 | 128,483 |
| 2014-12-01 | 0.625 | 5 | 8 | 62,000 | 126,158 |
| 2014-09-01 | 1.0 | 3 | 3 | 20,000 | 45,000 |
| 2014-06-01 | 0.9459 | 35 | 37 | 514,181 | 589,312 |
| 2014-03-01 | 10.0 | 10 | 1 | 142,524 | 40,000 |
| 2013-09-01 | 0.3333 | 1 | 3 | 50,000 | 109,858 |
| 2013-06-01 | 0.5455 | 18 | 33 | 310,016 | 504,087 |
| 2013-03-01 | 1.2857 | 9 | 7 | 385,000 | 179,973 |
| 2012-09-01 | 0.3333 | 8 | 24 | 102,000 | 400,000 |
| 2012-03-01 | 0.3846 | 5 | 13 | 160,000 | 341,551 |
| 2011-09-01 | 2.0 | 2 | 1 | 31,000 | 25,000 |
| 2011-03-01 | 0.25 | 1 | 4 | 5,000 | 85,000 |
| 2009-09-01 | 1.25 | 5 | 4 | 104,000 | 451,800 |
| 2008-09-01 | 3.0 | 6 | 2 | 109,000 | 10,000 |
| 2008-03-01 | 0.1304 | 3 | 23 | 115,000 | 76,368 |
| 2007-12-01 | 0.5556 | 10 | 18 | 155,400 | 92,600 |
| 2007-09-01 | 3.5 | 7 | 2 | 860,000 | 139,465 |
| 2007-06-01 | 1.2857 | 9 | 7 | 127,000 | 89,444 |
| 2007-03-01 | 0.3571 | 5 | 14 | 160,000 | 78,000 |
| 2006-09-01 | 2.2 | 11 | 5 | 108,000 | 65,000 |
| 2006-03-01 | 0.8333 | 15 | 18 | 596,500 | 236,400 |
| 2005-12-01 | 2.0 | 6 | 3 | 17,000 | 36,576 |
| 2005-09-01 | 0.4615 | 6 | 13 | 85,000 | 60,425 |
| 2005-06-01 | 6.0 | 6 | 1 | 175,000 | 15,000 |
| 2005-03-01 | 2.5 | 5 | 2 | 45,000 | 20,000 |
| 2004-09-01 | 6.0 | 6 | 1 | 85,000 | 24,000 |
| 2004-06-01 | 1.75 | 7 | 4 | 220,000 | 25,000 |
| 2004-03-01 | 0.5 | 1 | 2 | 5,000 | 5,000 |
| 2003-12-01 | 1.25 | 20 | 16 | 140,000 | 128,000 |
Repligen Notable Stakeholders
A Repligen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Repligen often face trade-offs trying to please all of them. Repligen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Repligen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anthony Hunt | President CEO, Director | Profile | |
| Olivier Loeillot | President Officer | Profile | |
| Ralf Kuriyel | Senior Vice President - Research & Development | Profile | |
| Mark Salerno | VP Analytics | Profile | |
| Christine Gebski | Senior Chromatography | Profile | |
| Kimberly Cornwell | General Counsel | Profile | |
| Dianne Heiler | Senior Sustainability | Profile | |
| James Bylund | Chief Officer | Profile | |
| Kola Otitoju | Senior Development | Profile | |
| Stephen Tingley | VP Sales | Profile | |
| Jaime Humara | Senior Marketing | Profile | |
| Jon Snodgres | Chief Officer | Profile | |
| Rachel Goodrich | VP Marketing | Profile | |
| Neil Whitfield | Vice Sales | Profile | |
| Leslie Galvin | Global Resources | Profile | |
| Keith Robinson | Chief Officer | Profile | |
| Sondra Newman | Global Relations | Profile | |
| Jason Garland | Chief Officer | Profile | |
| Craig Harrison | VP Analytics | Profile |
About Repligen Management Performance
The success or failure of an entity such as Repligen often depends on how effective the management is. Repligen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Repligen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Repligen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.02 | |
| Return On Equity | 0.02 | 0.02 |
Repligen Workforce Analysis
Traditionally, organizations such as Repligen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Repligen within its industry.Repligen Manpower Efficiency
Return on Repligen Manpower
| Revenue Per Employee | 358.3K | |
| Revenue Per Executive | 33.6M | |
| Net Income Per Employee | 23.3K | |
| Net Income Per Executive | 2.2M | |
| Working Capital Per Employee | 534.4K | |
| Working Capital Per Executive | 50.2M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repligen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Repligen Stock, please use our How to Invest in Repligen guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Repligen. If investors know Repligen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Repligen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.83) | Earnings Share (0.03) | Revenue Per Share 11.452 | Quarterly Revenue Growth 0.097 | Return On Assets 0.002 |
The market value of Repligen is measured differently than its book value, which is the value of Repligen that is recorded on the company's balance sheet. Investors also form their own opinion of Repligen's value that differs from its market value or its book value, called intrinsic value, which is Repligen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Repligen's market value can be influenced by many factors that don't directly affect Repligen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Repligen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Repligen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Repligen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.